Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Spanish Oncology Genito-Urinary Group
ClinicalTrials.gov Identifier:
NCT01514526
First received: December 21, 2011
Last updated: October 6, 2014
Last verified: October 2014
  Purpose
  • Design: non-randomized, open label, phase II clinical trial.
  • Study population and disease: adult patients with metastatic or locally advanced non-resectable adrenocortical carcinoma, confirmed histologically.
  • Estimated number of patients: 15.
  • Study drug: dovitinib (TKI-258), dosed on a flat scale of 500mg/day on a 5 days on / 2 days off.
  • Treatment duration: study treatment period will be continued until disease progression, unacceptable toxicity, death or premature withdrawal from study. An average of 6 months treatment period is expected.
  • Study duration: expected recruitment period will be 18 months, and patients will be followed for 6 additional months after last patient is included in the trial.Study total expected duration is 24 months.
  • Sites: the study is planned to be conducted in 7 Spanish centers.

Condition Intervention Phase
Adrenocortical Carcinoma
Drug: Dovitinib
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Clinical Trial of Dovitinib (TKI-258) in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma

Resource links provided by NLM:


Further study details as provided by Spanish Oncology Genito-Urinary Group:

Primary Outcome Measures:
  • Efficacy in terms of overall response rate (ORR) of dovitinib as treatment for metastatic or locally advanced non-resectable primary adrenocortical carcinoma (measured by an external evaluator) [ Time Frame: Up to 6 months (Study treatment expected duration) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Safety profile of dovitinib in study population [ Time Frame: Up to 24 months (Study expected duration, including patient treatment and follow up) ] [ Designated as safety issue: Yes ]
    Safety will be assessed considering the number of study participants with Adverse Events during the conduct of the trial, from date of patient inclusion until the date of study end, up to 24 months.

  • Efficacy of dovitinib in reducing ACC hormonal production (cortisol, testosterone, aldosterone or estrogens) [ Time Frame: Up to 6 months (Study treatment expected duration) ] [ Designated as safety issue: No ]
  • Progression free survival (PFS) in all treated patients (measured by an external evaluator) [ Time Frame: Up to 24 months (Study expected duration, including patient treatment and follow up) ] [ Designated as safety issue: Yes ]
    From date of patient inclusion until the date of first documented progression, assessed up to 24 months.

  • Overall survival (OS)(measured by an external evaluator) [ Time Frame: Up to 24 months (Study expected duration, including patient treatment and follow up) ] [ Designated as safety issue: Yes ]
    From date of patient inclusion until the date of of death from any cause, assessed up to 24 months.

  • Quality of Life (QoL) [ Time Frame: Up to 24 months (Study expected duration, including patient treatment and follow up) ] [ Designated as safety issue: No ]
    From date of patient inclusion until the date of study end, up to 24 months.

  • Progression Free Survival and Overall Survival (determined by the local researchers) [ Time Frame: Up to 24 months (Study expected duration, including patient treatment and follow up) ] [ Designated as safety issue: No ]
    From date of patient inclusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.


Enrollment: 17
Study Start Date: January 2012
Estimated Study Completion Date: January 2015
Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Dovitinib Drug: Dovitinib

Dovitinib (TKI-258), gelatin capsule of 100mg, developed and supplied by Novartis Inc. The study regimen consists of the administration of 500 mg / day (5 x 100mg) once daily, taken orally with a large amount of water, preferably one hour prior to a meal or at least two hours following a meal. This dose will be taken once daily according to 5 days on/2 days off schedule.

The patient will continue on treatment until disease progression,unacceptable toxicity, death or premature withdrawal.

Other Name: TKI258

Detailed Description:

Non applicable

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female patients aged ≥ 18 years old
  • A performance status of 0, 1, or 2, according to the Eastern Cooperative Oncology Group (ECOG) scale.
  • Histologically confirmed adrenocortical carcinoma.
  • Metastatic or locally advanced non-resectable disease.
  • At least one radiologically measurable lesion, according to RECIST 1.1.
  • Adequate liver function as shown by: serum or plasma ALT and AST ≤ 3.0 x ULN (regardless of the presence or absence of metastases)and serum or plasma total bilirubin: ≤ 1.5 x ULN.
  • Adequate bone marrow function as shown by: blood absolute neutrophil count (ANC) ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L and hemoglobin (Hb) > 9g/dL.
  • Adequate renal function as shown by serum creatinine ≤ 1.5 x ULN.
  • Patients give a written informed consent obtained according to local guidelines.

Exclusion Criteria:

  • Prior chemotherapy other than mitotane (Patients who have previously received mitotane will only be eligible if drig has been withdrawn at least two weeks earlier than dovitinib first dose is administered).
  • Patients with another primary malignancy within 3 years prior to starting the study drug, with the exception of adequately treated in-situ carcinoma of the uterine cervix, or completely excised basal or squamous cell carcinoma of the skin.
  • Patients who have received radical radiotherapy ≤4 weeks prior to starting the study treatment or who have not recovered from radiotherapy-related toxicities. Palliative radiotherapy for bone lesions ≤2 weeks prior to starting study treatment is allowed.
  • Patients who have undergone any major surgery (i.e., intra-thoracic, intrabdominal, or intra-pelvic) ≤4 weeks prior to starting study treatment or who have not recovered from side effects of such therapy.
  • Patients with a history of pulmonary embolism (PE) within the past 6 months or untreated deep-venous-thrombosis (DVT) within the past 6 months. Adequately treated DVT will be permitted providing that patient has been on anticoagulation for at least 2 weeks.
  • Patients with impaired cardiac function or clinically significant cardiac diseases, including any of the following:

    • History or presence of serious uncontrolled ventricular arrhythmias.
    • Clinically significant resting bradycardia.
    • LVEF <45% when assessed by 2-D echocardiogram (ECHO) or multiple gated acquisition scan (MUGA). (No basal cardiac test is mandatory other than ECG)
    • Any of the following within 6 months prior to starting study treatment: Myocardial infarction (MI), severe/unstable angina, Coronary Artery Bypass Graft (CABG), Congestive Heart Failure (CHF),Cerebrovascular Accident (CVA), Transient Ischemic Attack TIA).
    • Uncontrolled hypertension defined by a SBP ≥160 mm Hg and/or DBP ≥100 mm Hg, with or without anti-hypertensive medication. Initiation or adjustment of antihypertensive medication (s) is allowed prior to study entry.
  • Patients with impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of Dovitinib (TKI258) (i.e., severe ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or extensive (>1m) small bowel resection, inability to swallow oral medications). Prior partial or total gastrectomy is not an exclusion criterion.
  • Known diagnosis of human immunodeficiency virus (HIV) infection. HIV testing is not mandatory.
  • Patients who are currently receiving full dose of anticoagulation treatment with therapeutic doses of dicumarinical drugs as warfarin/acenocoumarol or anti-platelet therapy (i.e.,clopidogrel bisulfate). Treatment with acetylsalicyclic acid 100mg daily is allowed, as well as prophylactic or therapeutic low-weight-heparin.
  • Pregnant or breast-feeding women.
  • Women of child-bearing potential not employing an effective method of birth control. Effective contraception (e.g. condom with spermicidal jelly, foam suppository or film; diaphragm with spermicide; male condom and diaphragm with spermicide) must be used throughout the trial and 8 weeks after the end of Dovitinib treatment. Oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are therefore not considered effective for this study. Women of child-bearing potential defined as sexually mature women who have not undergone a hysterectomy or who have not been naturally postmenopausal for at least 12 consecutive months (i.e., who has had menses any time in the preceding 12 consecutive months), must have a negative serum pregnancy test ≤ 14 days prior to starting study drug. Women of child-bearing potential not employing and not willing to use an effective method of birth control. Post-menopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential.
  • Fertile males not willing to use contraception as stated above.
  • Patients unwilling or unable to comply with the protocol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01514526

Locations
Spain
Complejo Hospitalario Universitario de Santiago
Santiago de Compostela, A Coruña, Spain, 15706
Hospital Universitario Fundación de Alcorcón
Alcorcón, Madrid, Spain, 28922
Hospital del Mar
Barcelona, Spain, 08003
Hospital Universitario Reina Sofía
Córdoba, Spain, 14004
Hospital Universitario Central de Asturias
Oviedo, Spain, 33006
Complejo Hospitalario de Navarra
Pamplona, Spain, 31008
Fundación Instituto Valenciano de Oncología
Valencia, Spain, 46009
Sponsors and Collaborators
Spanish Oncology Genito-Urinary Group
Investigators
Principal Investigator: Jesús García-Donás Jiménez, MD Spanish Oncology Genito-Urinary Group
  More Information

Additional Information:
No publications provided

Responsible Party: Spanish Oncology Genito-Urinary Group
ClinicalTrials.gov Identifier: NCT01514526     History of Changes
Other Study ID Numbers: SOGUG2011-03, 2011-002873-47
Study First Received: December 21, 2011
Last Updated: October 6, 2014
Health Authority: Spain: Agencia Española de Medicamentos y Productos Sanitarios

Keywords provided by Spanish Oncology Genito-Urinary Group:
Adrenocortical carcinoma

Additional relevant MeSH terms:
Adrenocortical Carcinoma
Carcinoma
Adenocarcinoma
Adrenal Cortex Diseases
Adrenal Cortex Neoplasms
Adrenal Gland Diseases
Adrenal Gland Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial

ClinicalTrials.gov processed this record on October 29, 2014